FDA grants priority review to fluocinolone for DME

Atlanta? Alimera Sciences announced the FDA?s acceptance for filing and granting of priority review status for a new drug application (NDA) for fluocinolone acetonide intravitreal insert (Iluvien ).

Atlanta-Alimera Sciences announced the FDA’s acceptance for filing and granting of priority review status for a new drug application (NDA) for fluocinolone acetonide intravitreal insert (Iluvien).

The product is an investigative, extended-release intravitreal insert that the company is developing for the treatment of diabetic macular edema (DME). The insert is designed to have a therapeutic effect for up to 36 months and is inserted in the back of the eye in a manner facilitating a self-sealing wound.

“If approved,” said Dan Myers, president and chief executive officer of Alimera Sciences, “we believe that [fluocinolone acetonide] will be the first pharmaceutical in the United States indicated to treat this disease, and the first long-term treatment with the potential to be therapeutically effective for up to 36 months.”

FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists.

Alimera currently is conducting two phase III pivotal clinical trials for the intravitreal insert. The study will conclude later this year.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.